Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma
NCT03487133
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
32
Enrollment
OTHER
Sponsor class
Conditions
Relapsed and/or Refractory Cutaneous T-cell Lymphoma
Interventions
DRUG:
bortezomib/dexamethasone
Sponsor
Samsung Medical Center